Abstract
Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in
| Original language | English |
|---|---|
| Pages (from-to) | 3071-3076 |
| Number of pages | 6 |
| Journal | Anticancer Research |
| Volume | 22 |
| Issue number | 5 |
| Publication status | Published - Sep 2002 |
Fingerprint
Keywords
- Chemotherapy
- Colorectal cancer
- Elderly
- Raltitrexed
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. / Romiti, Adriana; Tonini, Giuseppe; Santini, Daniele; Di Seri, Marisa; Masciangelo, Raffaele; Mezi, Silvia; Verì, Attilio; Santuari, Lucia; Vincenzi, Bruno; Brescia, Antonio; Marchei, Paolo; Frati, Luigi; Tomao, Silverio.
In: Anticancer Research, Vol. 22, No. 5, 09.2002, p. 3071-3076.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer
AU - Romiti, Adriana
AU - Tonini, Giuseppe
AU - Santini, Daniele
AU - Di Seri, Marisa
AU - Masciangelo, Raffaele
AU - Mezi, Silvia
AU - Verì, Attilio
AU - Santuari, Lucia
AU - Vincenzi, Bruno
AU - Brescia, Antonio
AU - Marchei, Paolo
AU - Frati, Luigi
AU - Tomao, Silverio
PY - 2002/9
Y1 - 2002/9
N2 - Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in
AB - Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in
KW - Chemotherapy
KW - Colorectal cancer
KW - Elderly
KW - Raltitrexed
UR - http://www.scopus.com/inward/record.url?scp=0036765690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036765690&partnerID=8YFLogxK
M3 - Article
C2 - 12530045
AN - SCOPUS:0036765690
VL - 22
SP - 3071
EP - 3076
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5
ER -